Lead Investigator: Cosima Locher, University Hospital Zurich
Title of Proposal Research: Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An individual-patient data meta-analysis
Vivli Data Request: 8937, 6024
Funding Source: The project is part of a grant awarded to Dr. Cosima Locher by the Swiss National Science Foundation (SNSF; Project Number PZ00P1_201972)
Potential Conflicts of Interest: None
Summary of the Proposed Research:
Acronyms:
CPP – Chronic Primary Pain – Chronic Pain in one or more bodily regions, persists or recurs for more than three months and is associated with significant emotional distress and functional disability
IPD – Individual Patient Data – Study data from individual patients participating in the respective study
RCT – Randomized Controlled Trial – Most common trial design
Many studies in patients with chronic pain found that the effect of opioids was only moderate compared to placebo. At the same time, many patients show a relevant placebo response in clinical trials, and report significant pain relief. The placebo response is especially high in trials that examine an opioid, probably due to higher expectations regarding pain relief that patients have when entering such a trial. In our analysis, we use individual patient data from several studies to look at patient and trial differences that might help explain who experiences a high placebo response – and who does not. Further, we are also interested in the question whether the number of study arms influence the response of patients to both opioid and placebo. Therefore, we use data from studies that have already been conducted, and look at invididual differences rather than mean differences (of samples). This will allow us to gain more detailed knowledge about who is more likely to exhibit a high placebo response – and under which conditions.
Necessity of the research: The findings of this study will have implications for the interpretation and design of placebo-controlled clinical trials in the field of opioids. Detailed information about the placebo response and its determinants helps to interpret opioid-placebo differences (i.e., ‘assay sensitivity’) and, in turn, prevents an under- or overestimation of the specific opioid effect in comparison with nonspecific effects. This knowledge will also be of interest for clinicians and patients, enabling to design an evidence-based treatment plan.
How many patients are potentially affected: Patients already participated in the studies we aim to analyze. Thus, we will re-examine data that has been already collected. No additional effort is needed from patients’ side. However, the gained findings will be of general interest for patients with CPP being treated with opioids.
How the research will add to medical science or patient care: Future RCTs could try to minimize placebo responses and thereby limit their influence on the overall findings with different strategies: (a) to statistically control for patient characteristics shown to be related to placebo responses; and (b) to adapt the study design by considering trial characteristics associated with placebo responses. Furthermore, the findings will have implications for the clinical practice. There, the gained knowledge will allow to maximize and personalize placebo responses within an ethical framework (e.g., to foster a patient-physician relationship that is based on trust).
How the research will be conducted: We aim to conduct an individual patient data (IPD) meta-analysis. A meta-analysis combines various trials that have been already conducted, allowing to calculate an overall effect size. In a first step, the original trial data will be sought from the sponsors and / or authors of all studies fulfilling the inclusion criteria. In a second step, we will combine the study data into one master file. Then, we will calculate the placebo effect size and its determinants.
What design and methods you have chosen and why: We did choose to use an IPD. Data sharing agreements make it possible for researchers to apply IPD instead of aggregate data. IPD results in more clinically relevant results than a meta-analysis of aggregate data, going beyond the “grand mean” toward individualized medicine. Thus, the estimation of results for each covariate value allows different recommendations to be made for different subgroups of patients; personalising treatment in this way can benefit patients and ensure the cost‐effective use of health.
Requested Studies:
A Phase 2, Randomized Withdrawal Study of the Analgesic Efficacy and Safety of Hydrocodone/Acetaminophen Extended Release Compared to Placebo in Subjects With Chronic Low Back Pain
Sponsor: AbbVie
Study ID: NCT01364922
Sponsor ID: M12-807
A Phase 3, Open-Label Period Followed By a Randomized, Double-Blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) Compared to Placebo in Subjects With Chronic Low Back Pain
Sponsor: Abbvie
Study ID: NCT00325949
Sponsor ID: M05-790
A Phase 3, Open-Label Period Followed by a Randomized, Double-blind, Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain
Sponsor: AbbVie
Study ID: NCT00761150
Sponsor ID: M10-385
A Phase 3, Open-Label Period Followed by a Randomized, Double-blind Placebo-controlled Study of the Analgesic Efficacy of Extended-release Hydrocodone/Acetaminophen (Vicodin CR) Compared to Placebo in Subjects With Chronic Low Back Pain
Sponsor: AbbVie
Study ID: NCT00763321
Sponsor ID: M10-277
Update: This data request was withdrawn on 11-Jan-2022 by the researcher.
(Note: Additional study added as part of data request 8937)
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE‑CONTROLLED, MULTICENTER, PARALLEL‑GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Data Contributor: Pfizer Inc.
Study ID: NCT02528253
Sponsor ID: NCT02528253